Litcius/Paper detail

Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY

Kozo Kataoka, Ken Mori, Yuichi Nakamura, Junichiro Watanabe, Naoya Akazawa, K. Hirata, Mitsuru Yokota, Kimi Kato, Masahito Kotaka, K. Yamazaki, Yoshinori Kagawa, Saori Mishima, Koji Ando, Masaaki Miyo, Hiroki Yukami, G. Laliotis, Shruti Sharma, Charuta C. Palsuledesai, Marian Rabinowitz, Adham Jurdi, M C Liu, Alexey Aleshin, Daisuke Kotani, Hideaki Bando, H. Taniguchi, Ichiro Takemasa, Takeshi Kato, Takashi Yoshino, Eiji Oki

2024Annals of Oncology34 citationsDOI

Topics & Concepts

MedicineColorectal cancerOncologyAdjuvant chemotherapyInternal medicineChemotherapyAdjuvantCirculating tumor DNADiseaseMinimal residual diseaseRisk stratificationCancerBreast cancerLeukemiaCancer Genomics and DiagnosticsCancer Cells and MetastasisColorectal Cancer Treatments and Studies
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY | Litcius